Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations. Issue 4 (14th March 2016)

• Record Type: Journal Article
• Authors: Hamilton, Betty Ky; Visconte, Valeria; Jia, Xuefei; Tabarroki, Ali; Makishima, Hideki; Hasrouni, Edy; Abounader, Donna; Kalaycio, Matt; Sekeres, Mikkael A.; Sobecks, Ronald; Duong Liu, Hien; Bolwell, Brian; Maciejewski, Jaroslaw P.; Copelan, Edward; Tiu, Ramon V.
• Is Part Of: American journal of hematology. Volume 91:Issue 4(2016:Apr.)
• Page Start: 406
• Page End: 409
• Publication Date: 2016-03-14
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.24306
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract : Molecular predictors of outcome are increasingly important in determining optimal therapy for myeloid neoplasms. Mutations in the spliceosomal genes ( U2AF1 and SRSF2 ) predict for poor outcomes in myelodysplastic syndromes (MDS) and related diseases. We investigated the effect of hematopoietic cell transplant (HCT) on the negative prognostic impact of U2AF1 and SRSF2 mutations. In total, 122 patients with MDS (30%), acute myeloid leukemia (51%), myeloproliferative neoplasms (MPN) (11%), and MDS/MPN (8%) receiving a HCT from 2003 to 2012 were evaluated for mutations in U2AF1 and SRSF2 by direct sequencing. Median time of follow up was 24 months (range 0.46–110). SRSF2 mutations were detected in 11 (10%) patients and U2AF1 in 3 (3%) patients. There were no significant differences in baseline characteristics between mutated and wild‐type (WT) patients. Patients carrying SRSF2 and U2AF1 mutations had similar overall survival ( P = 0.84), relapse mortality ( P = 0.50), and non‐relapse mortality ( P = 0.72) compared to WT patients. However, taking into account disease status and cytogenetics in a subset of AML patients, SRSF2 and U2AF1 mutations were associated with worse survival (HR 3.71, P = 0.035). Am. J. Hematol. 91:406–409, 2016. © 2016 Wiley Periodicals, Inc.